- Home
- PZG vs MAIA Comparison
PZG vs MAIA Comparison
Compare PZG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZG
- MAIA
- Stock Information
- Founded
- PZG 1992
- MAIA 2018
- Country
- PZG United States
- MAIA United States
- Employees
- PZG N/A
- MAIA N/A
- Industry
- PZG Metal Mining
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PZG Basic Materials
- MAIA Health Care
- Exchange
- PZG Nasdaq
- MAIA Nasdaq
- Market Cap
- PZG 48.4M
- MAIA 56.3M
- IPO Year
- PZG 1999
- MAIA 2022
- Fundamental
- Price
- PZG $1.05
- MAIA $1.61
- Analyst Decision
- PZG
- MAIA
- Analyst Count
- PZG 0
- MAIA 0
- Target Price
- PZG N/A
- MAIA N/A
- AVG Volume (30 Days)
- PZG 877.1K
- MAIA 468.7K
- Earning Date
- PZG 11-11-2025
- MAIA 11-11-2025
- Dividend Yield
- PZG N/A
- MAIA N/A
- EPS Growth
- PZG N/A
- MAIA N/A
- EPS
- PZG N/A
- MAIA N/A
- Revenue
- PZG N/A
- MAIA N/A
- Revenue This Year
- PZG N/A
- MAIA N/A
- Revenue Next Year
- PZG N/A
- MAIA N/A
- P/E Ratio
- PZG N/A
- MAIA N/A
- Revenue Growth
- PZG N/A
- MAIA N/A
- 52 Week Low
- PZG $0.31
- MAIA $1.40
- 52 Week High
- PZG $1.20
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- PZG 54.59
- MAIA 50.48
- Support Level
- PZG N/A
- MAIA $1.54
- Resistance Level
- PZG $1.07
- MAIA $1.78
- Average True Range (ATR)
- PZG 0.07
- MAIA 0.09
- MACD
- PZG -0.04
- MAIA 0.02
- Stochastic Oscillator
- PZG 87.50
- MAIA 45.31
About PZG Paramount Gold Nevada Corp.
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.